COSA 2017November 13 - 15, 2017

Breakfast Sessions

Monday 13th November

Building effective enterprise data solutions to support both practice and research. Meeting the needs of technologists and clinicians

Time: 7:00 - 8:15am
Date: Monday 13th November 2017
Description: How we develop and use health data systems to support clinician decision making and research in cancer is a national priority. This workshop will explore this topic through a discussion with national and international leaders from both a technical, governance and clinical perspective. You will take away from the workshop an understanding of where we are at and how all the pieces of this complex jigsaw puzzle can fit together.

Chair: TBA
Speaker: 
Dana Rollison 

This breakfast session is supported by COSA 
COSA Logo BLUE RGB 72dpi

Tuesday 14th November

2nd line NSCLC - how new therapies are changing the Australian treatment landscape

Time: 07:00 - 08:45am 
Date: Tuesday 14th November 2017
Description: In 2017 the Australian treatment landscape in 2nd line non-small cell lung cancer (NSCLC) continues to rapidly change and evolve. New therapies in both non-mutation and mutation driven disease have recently become available allowing for greater choice in the treatment of this devastating disease.  The question now has become, how do these therapies differ and which of these differentiating factors are important to both clinicians and patients. Lastly, in this era of changing medicine with different mode of actions and corresponding side effect profiles, who else needs to be involved to ensure optimal care of 2nd line NSCLC? In this Roche-sponsored breakfast symposium Dr Adnan Nagrial will discuss “Treatment choices and managing patients with non-mutation 2nd line NSCLC” and Dr Steven Kao will discuss “2nd line ALK and NSCLC - approach to targeted therapies".  Prof Stephen Clarke will chair this session which aims to give Australian oncologists practical guidance on differentiating/choosing therapies and managing patients the rapidly evolving treatment landscape, particularly focusing on recent data and new therapies available to 2nd line NSCLC patients. 

Chair: Professor Stephen Clarke, Royal North Shore Hospital
Speakers:
Dr Adnan Nagrial, Crown Princess Mary Cancer Centre Westmead - "Managing patients with non-mutation 2nd line NSCLC" 
Dr Stephen Kao, Chris O'Brien Lifehouse - "Mutation driven 2nd line NSCLC - approach to targeted therapies" 

This breakfast session is supported by Roche

Roche blue logo

 

Cancer Pain Symposium

Time: 7:00 - 8:45am
Date: Tuesday 14th November 2017
Description: This symposium will be an update on the current management of cancer pain, exploring the current basis of treatment and its limitations and discussing alternative management options in common practice in the U.S.A and Europe. The first session by Professor Paul Glare will discuss Opiate medication, its development as the mainstay of cancer pain management and the W.H.O model. Despite this development, opioids have limited efficacy and the model of cancer pain management has not changed despite the enormous progress seen in oncology treatment. Furthermore, with oncological advances the profile of the patient during or post cancer treatment specifically has changed drastically in the lifespan of the W.H.O model. Additionally, the landscape of opiate misuse has changed drastically with Australia experiencing an “opioid epidemic”. Chronic non-cancer pain management has altered in this time to carefully protocolised opioid therapy. Cancer pain management is still considered as a separate entity to non-cancer pain management, however, considerable overlap exists with the oncology patient experiencing multiple non oncological morbidities. Many further similarities exist between these populations and therefore chronic non-cancer pain management can be adapted to provide multidisciplinary, efficacious and non opioid based pain solutions in patients with cancer. The second session from Dr Tim Hucker will discuss non opioid medication and interventional options for cancer pain management. europathic pain is prevalent in cancer, either from the cancer itself or its treatment and throughout the cancer journey. Even in survivorship, neuropathic pain is common and persistent. The limitation of efficacy in opiate management of neuropathic pain will be highlighted. Despite being part of cancer pain management guidelines and contrary to other countries, interventional pain options are infrequently considered. There are a wide variety of pain syndromes in the cancer patient and interventional options exist in many situations. The careful application of interventional techniques in this population will aid efficacy and also assist in limiting opiate related side effects and wider opiate burden.

Chair: Tim Hucker
Speakers: Tim Hucker & Paul Glare

This breakfast session is supported by Medtronic

 art logo cmyk bl eps 01

Wednesday 15th November

Moving Mountains in NSCLC - The New Era of IO for 1L Lung Cancer Treatment

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017
Description: Please join us for a scientific update on new treatment paradigms in 1L lung cancer and how these will impact clinical outcomes, with a specific focus on the role of immunotherapy.

Chair: Associate Professor Rina Hui, Westmead Hospital
Speaker: A/Prof Rina Hui, Crown Princess Mary Cancer Centre Westmead - " Immunotherapy in First-line NSCLC: Where are we now?"
A/Prof Wendy Cooper, Royal Prince Alfred Hospital - "Practical application of PD-L1 testing in 1L NSCLC"
Beth Ivimey, Bankstown Hospital “Patient management : lung clinical nurse coordinator perspective”

This breakfast session is supported by MSD

MSD logo2

Becoming a pro with PRO

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017
Description: There is growing evidence that incorporating patient reported outcomes (PROs) into the care of patients with cancer is beneficial to patient care and health system planning. However, implementing PROs into routine practice is a complex undertaking that requires appropriate planning and support. In this session we will briefly review some of the history and evidence for use of PROs in oncology and spend the majority of our time discussing implementation issues drawing on existing experiences across healthcare systems and discuss approaches for successful implementation using a case-based approach.

Chair: Afaf Girgis

Speaker: Dr. Monika Krzyzanowska

This breakfast session is supported by COSA 
COSA Logo BLUE RGB 72dpi Copy

 

Scalp Cooling - Meeting the Growing Demand

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017
Description: Professor Boyle will review the latest international clinical data and the CHILL registry and Quality of Life (QOL) Tool.  Fran will also provide their centre’s feedback on the next generation Paxman cooling cap. Dr Michelle White has been instrumental in introducing scalp cooling both into the private and public sectors.  Michelle will share her experiences, challenges and successful strategies to introduce scalp cooling within both sectors.  Abby Fyfe will discuss some of their challenges and successes in implementing scalp cooling to their patients.  Following the presentations there will be a panel discussion on scalp cooling experiences and questions from the audience.

Chair: Dr Michelle White, Oncologist, Monash Health and Cabrini
Speaker: Professor Fran Boyle, Medical Oncologist, Mater Hospital North Sydney
Dr Michelle White, Medical Oncologist, Monash Health and Cabrini Health
Ms Abby Fyfe, Nurse Unit Manager, Macquarie University Hospital

This breakfast session is supported by Regional Healthcare Group

logo p

Exploring the forgotten genome of cancer research

Time: 7:00 - 8:45am
Date: Wednesday 14th November 2017
Description: Sarcomas are a rare, phenotypically heterogeneous family of cancers that disproportionately affects the young. Although the study of rare sarcoma families has contributed richly to cancer biology, the genetic architecture of cancer risk has not previously been studied in the sarcoma population. Professor Thomas will discuss the International Sarcoma Kindred Study (ISKS) and how a unique genetic panel of genes associated with cancer risk has been developed. The frequency of potentially actionable monogenic and polygenic germline variants in the ISKS cohort warrants attention as personalized medicine evolves, with special relevance to other young-onset cancers.

Chair: Kahlil Lawless
Speaker: David Thomas, Garvan Institute of Medical Research, The Kinghorn Cancer Centre

This breakfast session is supported by Illumina

Illumina